期刊
ONCOLOGIST
卷 17, 期 1, 页码 46-54出版社
WILEY
DOI: 10.1634/theoncologist.2011-0227
关键词
Sarcomatoid; Renal cell carcinoma; Kidney cancer
类别
资金
- GlaxoSmithKline
- NIH, National Cancer Institute, Center for Cancer Research
- NATIONAL CANCER INSTITUTE [Z01BC011028, Z01BC011023, ZIDBC011089, ZIABC011038, ZIABC011043, Z01BC011089, ZIABC011028] Funding Source: NIH RePORTER
Recent advancements in the molecular characterization of renal cell carcinoma altered the classification system and now kidney cancer is divided into several distinct histologic subtypes. Although once a separate histologic category, sarcomatoid renal cell carcinoma is no longer considered a separate tumor type because it can occur with all histologic subtypes. Limited research on tumors with sarcomatoid change has led to minimal progress in the understanding and treatment of these tumors. Because the sarcomatoid variant of renal cell carcinoma can account for approximately one in six cases of advanced kidney cancer, we hope to familiarize clinicians with these tumors by describing the historic background, histologic features, molecular characterization, diagnosis, prognosis, treatment strategies, and active clinical trials of this aggressive type of tumor. The Oncologist 2012; 17: 46-54
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据